Dabigatran Etexilate A New Oral Thrombin Inhibitor

被引：257

作者：

Hankey, Graeme J. ^{[1
]}

Eikelboom, John W. ^{[2
]}

机构：

[1] Royal Perth Hosp, Stroke Unit, Dept Neurol, Perth, WA 6001, Australia

[2] McMaster Univ, Dept Med, Hamilton, ON, Canada

来源：

CIRCULATION | 2011年 / 123卷 / 13期

关键词：

anticoagulants; atrial fibrillation; dabigatran etexilate; direct thrombin inhibitor; stroke; NONVALVULAR ATRIAL-FIBRILLATION; TOTAL HIP-REPLACEMENT; RE-LY TRIAL; TRANSIENT ISCHEMIC ATTACK; VENOUS THROMBOEMBOLISM; STROKE PREVENTION; TOTAL KNEE; INDEPENDENT INHIBITORS; ANTITHROMBOTIC THERAPY; HEPARIN-ANTITHROMBIN;

D O I：

10.1161/CIRCULATIONAHA.110.004424

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：1436 / 1450

页数：15

共 72 条

[51] Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor [J].

Stangier, Joachim ;

Clemens, Andreas .

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2009, 15 :9S-16S

[52] Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate An Open-Label, Parallel-Group, Single-Centre Study [J].

Stangier, Joachim ;

Rathgen, Karin ;

Stahle, Hildegard ;

Mazur, Dago .

CLINICAL PHARMACOKINETICS, 2010, 49 (04) :259-268

[53]

Stangier J, 2009, AM J CARDIOVASC DRUG, V9, P59, DOI 10.2165/00129784-200909010-00006

[54] Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment [J].

Stangier, Joachim ;

Staehle, Hildegard ;

Rathgen, Karin ;

Roth, Willy ;

Shakeri-Nejad, Kasra .

JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (12) :1411-1419

[55]

STILES S, ORAL ANTICOAGULANTS

[56]

STILES S, WARFARIN MOVE DABIGA

[57] Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends [J].

Sun, Jack C. J. ;

Davidson, Michael J. ;

Lamy, Andre ;

Eikelboom, John W. .

LANCET, 2009, 374 (9689) :565-576

[58] The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile [J].

Testa, Luca ;

Bhindi, Ravinai ;

Agostoni, Pierfrancesco ;

Abbate, Antonio ;

Zoccai, Guiseppe G. L. Biondi ;

van Gaal, William J. .

EXPERT OPINION ON DRUG SAFETY, 2007, 6 (04) :397-406

[59] Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery [J].

Troconiz, Inaki E. ;

Tillmann, Christiane ;

Liesenfeld, Karl-Heinz ;

Schaefer, Hans-Guenter ;

Stangier, Joachim .

JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (03) :371-382

[60]

*USFDA ADV COMM, 2010, RISK MYOC INF, P22

← 1 2 3 4 5 6 7 8 →